Just how feasible is pharmacogenetic testing in the primary healthcare setting?

Pharmacogenomics

Volumn 13, Issue 5, 2012, Pages 507-509

  Swen, Jesse J ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

implementation; pharmacogenetic testing; pharmacogenetics; primary care

Indexed keywords

NORTRIPTYLINE;

CLINICAL EFFECTIVENESS; CYP2D6 GENE; DRUG DNA INTERACTION; DRUG METABOLISM; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; GENE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; GENOTYPE; ONCOLOGY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; REPRODUCIBILITY; REVIEW;

GENETIC TESTING; PHARMACOGENETICS; PRIMARY HEALTH CARE;

EID: 84859227444     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.19     Document Type: Review

References (15)

1. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA 285(5), 540-544 (2001). (Pubitemid 32656320)
2. Altman RB. Pharmacogenomics: 'noninferiority' is sufficient for initial implementation. Clin. Pharmacol. Ther. 89(3), 348-350 (2011).
3. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in The Netherlands. Arch. Intern. Med. 168(17), 1890-1896 (2008).
4. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286(18), 2270-2279 (2001). (Pubitemid 33063150)
5. Grice GR, Seaton TL, Woodland AM, McLeod HL. Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics 7(1), 61-65 (2006).
6. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol. Med. 7(5), 201-204 (2001). (Pubitemid 32822891)
7. Khoury MJ, Gwinn M, Dotson WD, Bowen MS. Is there a need for PGxceptionalism? Genet. Med. 13(10), 866-867 (2011).
8. van Schie RM, de Boer A, Maitland-van der Zee AH. Implementation of pharmacogenetics in clinical practice is challenging. Pharmacogenomics 12(9), 1231-1233 (2011).
9. Dolgin E. Preemptive genotyping trialed to prevent adverse drug reactions. Nat. Med. 17(11), 1323 (2011).
10. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet. Genomics 15(5), 365-369 (2005). (Pubitemid 40676559)
11. Stanek EJ, Sanders CL, Taber KA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450-458 (2012).
12. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat. Rev. 34(7), 656-669 (2008).
13. Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin. Pharmacol. Ther. 89(5), 662-673 (2011).
14. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2), 321-326 (2012).
15. Allison M. US pharmacies broaden access to pharmacogenetic tests. Nat. Biotechnol. 28(4), 299-300 (2010).